US equities |
MU $989.04 ▼-3.88% META $742.96 ▲+3.38% NVDA $226.32 ▼-1.29% SNDK $1,487.33 ▼-5.97% SPCX $163.42 ▲+0.52% MSFT $541.15 ▲+1.14% AMD $594.24 ▼-2.28% AAPL $340.97 ▲+1.29%
FinancialContent

AtaiBeckley Inc. - Common Stock (NQ:ATAI)

7.350 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AtaiBeckley Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
News headline image
Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? ↗
The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions. 
Via The Motley Fool
Atai Beckley (NASDAQ:ATAI) Clears Minervini Trend Template and High-Growth Momentum Screen ↗
Via Chartmill
News headline image
Why Eli Lilly Stock Climbed Today ↗
Demand for the healthcare leader's weight-loss drugs continues to rise. 
Via The Motley Fool
News headline image
Forget Weight Loss Drugs: Here's Another Reason to Buy Eli Lilly Stock ↗
Lilly's pipeline is on track to pick up a handful of interesting new programs. 
Via The Motley Fool
News headline image
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet. ↗
Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market. 
Via The Motley Fool
Topics ETFs Government
News headline image
Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs ↗
The company isn't resting on its laurels. 
Via The Motley Fool
News headline image
Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know. ↗
Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline. 
Via The Motley Fool
Unusual volume stocks in Monday's session ↗
Via Chartmill
News headline image
Why AtaiBeckley Stock Soared Today ↗
The psychedelic drugmaker is being acquired. 
Via The Motley Fool
News headline image
Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion ↗
Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments. 
Via The Motley Fool
Topics Government Stocks
What's going on in today's session ↗
Via Chartmill
Curious about the most active stocks on Thursday? ↗
Via Chartmill
Thursday's session: top gainers and losers ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. Agape ATP (NASDAQ:ATPC) shares moved... 
Via Benzinga
News headline image
What This $496,000 Insider Sale at AtaiBeckley Means Amid Roughly 100% Stock Run ↗
Hershberg exercised vested options and liquidated them under a Rule 10b5-1 plan, halving direct equity while retaining 404,869 derivative securities. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
These 3 Psychedelic Stocks Activated After Trump's Executive Order ↗
Via MarketBeat
Topics Government
After Fifteen Years, Tim Cook Steps Down, Wall Street Steps Back, Oil Steps Up ↗
Via Chartmill
News headline image
Why AtaiBeckley Stock Surged Today ↗
President Trump wants to fast-track psychedelic research. 
Via The Motley Fool
Topics Government
News headline image
This 4/20, Wall Street Is Betting on More Than Marijuana ↗
Via MarketBeat
News headline image
AtaiBeckley Stock Skyrockets After Cantor Fitzgerald's Overweight Rating ↗
AtaiBeckley (NASDAQ:ATAI) shares are surging Monday as psychedelic biotechs rally on President Trump's executive order to fast-track reviews. 
Via Benzinga
Topics Government
What's going on in today's session ↗
Via Chartmill
News headline image
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar ↗
Trump is easing approval for psychedelic treatments for mental disorders. 
Via The Motley Fool
Topics Government
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics
Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more... 
Via Finterra
Topics Cannabis Initial Public Offering Intellectual Property
News headline image
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 ↗
Via MarketBeat
News headline image
GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment ↗
GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression. 
Via Stocktwits
News headline image
MarketBeat’s Top 5 Rated Small-Cap Stocks ↗
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >